TCR² releases early data from some PhI patients, sparking optimism from analysts

A little over a year and a half since its $100M-plus IPO, immunotherapy biotech TCR² Therapeutics $TCRR released the first data from Phase I/II trials for its lead T cell therapy today, with some analysts expressing optimism from the results.